0001209191-23-059289.txt : 20231219
0001209191-23-059289.hdr.sgml : 20231219
20231219212510
ACCESSION NUMBER: 0001209191-23-059289
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231216
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Saad Kareem
CENTRAL INDEX KEY: 0001873805
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39482
FILM NUMBER: 231499166
MAIL ADDRESS:
STREET 1: C/O SEMA4 HOLDINGS CORP
STREET 2: 333 LUDLOW STREET, NORTH TOWER, 8TH FL.
CITY: STAMFORD
STATE: CT
ZIP: 06902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GeneDx Holdings Corp.
CENTRAL INDEX KEY: 0001818331
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 851966622
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 LUDLOW STREET
STREET 2: NORTH TOWER, 8TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 617 780 8742
MAIL ADDRESS:
STREET 1: 333 LUDLOW STREET
STREET 2: NORTH TOWER, 8TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
FORMER COMPANY:
FORMER CONFORMED NAME: Sema4 Holdings Corp.
DATE OF NAME CHANGE: 20210721
FORMER COMPANY:
FORMER CONFORMED NAME: CM Life Sciences, Inc.
DATE OF NAME CHANGE: 20200715
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-16
0
0001818331
GeneDx Holdings Corp.
WGS
0001873805
Saad Kareem
C/O GENEDX HOLDINGS CORP.
333 LUDLOW ST, NORTH TOWER
STAMFORD
CT
06902
0
1
0
0
Chief Transformation Officer
0
Class A Common Stock
2023-12-16
4
M
0
5114
0.00
A
25646
D
Class A Common Stock
2023-12-18
4
S
0
1700
2.1594
D
23946
D
Restricted Stock Unit
2023-12-16
4
M
0
5114
0.00
D
Class A Common Stock
5114
66476
D
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
/s/ Devin Schaffer, Attorney-in-Fact
2023-12-19